Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Mesoblast Limited ( (AU:MSB) ) is now available.
Mesoblast Limited has applied for quotation on the ASX of 3,050,000 ordinary fully paid shares, issued on March 25, 2026 under an employee incentive scheme. The new securities, which are to be quoted despite any transfer restrictions, modestly increase the company’s free float and reflect the ongoing use of equity-based remuneration to align staff incentives with shareholder interests.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.23 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company listed on the ASX under the code MSB. The company focuses on developing and commercializing cellular medicines, with its securities actively traded on the Australian market as ordinary fully paid shares.
Average Trading Volume: 4,151,861
Technical Sentiment Signal: Sell
Current Market Cap: A$2.8B
For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.